Gsk (GSK) Other Working Capital Changes (2009 - 2024)
Gsk (GSK) posted quarterly Other Working Capital Changes of $68.8 million for Q1 2026, up 108.92% year-over-year from $32.9 million in Q1 2025, and up 109.13% quarter-over-quarter from -$752.9 million in Q4 2025.
Gsk (GSK) Other Working Capital Changes (2009 - 2024) Analysis & Trends
Gsk's Other Working Capital Changes history runs 18 years deep, the most recent figure standing at $68.8 million for Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 108.92% year-over-year to $68.8 million; the TTM figure through Mar 2026 stood at -$1.4 billion (up 54.05% YoY), while the FY2025 annual figure was -$1.1 billion, down 137.11% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at $68.8 million, up from -$752.9 million in the prior quarter.
- The five-year high for Other Working Capital Changes was -$394.5 million in Q1 2024, with the low at -$1.0 billion in Q1 2023.
- The 4-year median for Other Working Capital Changes is -$693.0 million (2021), against an average of -$700.4 million.
- The sharpest annual moves came in 2022 and 2025: Other Working Capital Changes soared 135.46% in 2022, then sank 2356.07% in 2025.
- Gsk's Other Working Capital Changes stood at -$116.1 million in 2022, then sank by 1605.89% to -$2.0 billion in 2023, then surged by 101.68% to $33.4 million in 2024, then tumbled by 2356.07% to -$752.9 million in 2025, then soared by 109.13% to $68.8 million in 2026.
- Business Quant data shows GSK's Other Working Capital Changes at $68.8 million in Q1 2026, -$752.9 million in Q4 2025, and -$770.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -394.51 Mn |
| Mar 31, 2024 | -394.51 Mn |
| Mar 31, 2024 | -394.51 Mn |
| Mar 31, 2023 | -1.02 Bn |
| Mar 31, 2023 | -1.02 Bn |
| Mar 31, 2023 | -1.02 Bn |
| Mar 31, 2022 | -642.74 Mn |
| Mar 31, 2022 | -642.74 Mn |
| Mar 31, 2022 | -642.74 Mn |
| Mar 31, 2021 | -743.24 Mn |
| Mar 31, 2021 | -743.24 Mn |
| Mar 31, 2021 | -743.24 Mn |
| Dec 31, 2010 | 1.17 Bn |
| Dec 31, 2010 | 1.17 Bn |
| Dec 31, 2010 | 1.17 Bn |
| Sep 30, 2010 | 141.10 Mn |
| Sep 30, 2010 | 141.10 Mn |
| Sep 30, 2010 | 141.10 Mn |
| Dec 31, 2009 | 372.43 Mn |
| Dec 31, 2009 | 372.43 Mn |